Search Results

- Funding combines equity investment and convertible loan - Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody - Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs - Dr. Thomas Hecht has joined Board of Directors

The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic review but will eventually be let go.

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out after reportedly sparring with other agency officials over communications strategy; Eli Lilly’s first Phase III readout for oral obesity drug orforglipron missed analyst expectations; and Arrowhead Pharmaceuticals addresses the recent woes of its of partner Sarepta.

President Donald Trump loves a deal, but Most Favored Nation drug pricing isn’t a good one for anyone.

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.”

Insmed’s Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the market.